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ABSTRACT
Background: 
Advances in outpatient and supportive care and
increased pressure on hospital bed usage has led to 
the investigation of hospital in the home (HITH)
management following autologous haematologous stem
cell transplantation (AutoHSCT) for patients with
multiple myeloma or lymphoma.
Design: 
The Newcastle Mater Hospital Haematology Unit
together with the Mater Acute Care Community
Service (MACCS) developed a protocol for HITH care
following AutoHSCT.
Outcomes: 
Clinical outcomes of the protocol were audited:
40% (13) of patients were suitable candidates for HITH
care post transplantation. Of these 84.6% (11) were
readmitted to the haematology unit within seven days
of discharge from hospital.
Conclusion: 
Our preliminary experience suggests that with
adequate infrastructure support and rigorous patient
selection this model of care is both safe and feasible.
BACKGROUND
Recent advances in health care delivery haveallowed the treatment of patients at home whowould otherwise have previously been treated in
hospital. Hospital in the home (HITH) refers to the
delivery of acute hospital care to patients at home. HITH
may either substitute for the entire in-hospital admission
(pure HITH) or a part of the hospital admission (mixed
HITH). In Australia, HITH covers a diverse range of
conditions, programs, providers and funding arrangements
(Ruth et al 2001).
LITERATURE REVIEW
Data regarding outcomes of HITH are contradictory. A
number of studies, including some randomised controlled
studies, have shown that HITH is safe; that patient
outcomes in many conditions are equivalent for patients
using HITH and in-hospital care (IHC); and that both
perceived quality of life and patient satisfaction are
greater with HITH than with IHC (Davies et al 2000;
Caplan et al 1999; Montalto 1998; Donald et al 1995;
Cummings et al 1990). Two systematic reviews of HITH
have been performed and each found no significant
difference in health outcomes between HITH and IHC
(Shepperd and Iliffe 2000; Soderstrom et al 1999). In
part, these results reflect the fact that HITH has been
applied to a wide range of conditions and therapies, and
that outcomes of HITH may vary as a result.
In recent years, developments in chemotherapeutics
and supportive care have made outpatient care of a
number of haematological malignancies a possibility.
Outpatient management has been shown to be a safe,
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well-accepted and cost-efficient option in the treatment of
a number of conditions including: febrile neutropenia
related to chemotherapy, acute promyelocytic leukaemia
and acute myeloid leukaemia. (Paganini et al 2003; 
Allen et al 2001; Johansson et al 2001; Aquino et al 
2000; Girmenia et al 1999; Ruiz-Arguelles et al 1999;
Lowenthal et al 1996).
Developments in therapeutics and supportive care 
have also made HITH care for varying types of haemato-
poietic transplantation a possibility. Autologous stem cell
transplants, reduced-intensity allografts and conventionally
conditioned allografts have all been successfully performed
on an outpatient basis. The majority of experience has been
with granulocyte-colony stimulating factor (G-CSF)
supported autologous bone marrow or peripheral blood
stem cell (PBSC) transplantation. Results from published
studies suggest that outpatient autologous haematopoietic
stem cell transplantation (HSCT) can be performed safely
for patients with metastatic breast cancer and multiple
myeloma, with reduced length of stay and hospital charges,
without evidence of increased clinical complications or
out-of-pocket expenses to patients (Rizzo et al 1999;
Meisenberg 1997; Peters et al 1994; Sullivan et al 1994).
There are smaller numbers of reports of allogeneic
HSCT being performed on an outpatient basis, although
both myeloablative and non-myeloablative, reduced-
intensity transplants have been performed in the ambul-
atory setting. The development of non-myeloablative
conditioning protocols, in particular, has made routine
outpatient HSCT a distinct possibility.
A number of studies have demonstrated that 
non-myeloablative allogeneic transplantation using both
immunosuppressive, fludarabine-based conditioning
regimens, and radiotherapy-based conditioning regimens
is feasible and is not associated with a higher treatment
related mortality (TRM) or a higher rate of long-term
complications. It is acceptable to patients and their
families, is less emotionally distressing for caregivers of
HSCT recipients, is more able to meet their needs, and is
achievable in the majority of patients (Ruiz-Arguelles
2001; Grimm et al 2000; Ruiz-Argelles 2000; Algara
1994). Furthermore small studies of HITH following
conventional allografting has suggested that it may be
associated with several advantages including: faster
discharge; reduced need for total parental nutrition
(TPN); a lower incidence of acute graft versus host
disease (GvHD); lower TRM; and lower costs, although
these findings require confirmation in large prospective
randomized studies (Svahn et al 2002).
Of the published studies of HITH following autologous
transplantation, the majority report experience from the
United States of America. There are no published reports
of HITH care for transplantation in an Australian setting.
In this paper we report feasibility data from an audit of an
Australian haematology unit’s experience of partial
episode substitution (mixed HITH) following high-dose
chemotherapy and autologous stem cell transplantation
for patients with Hodgkin’s lymphoma, non-Hodgkin’s
lymphoma and multiple myeloma.
METHOD
For the purpose of reviewing the protocol development
of HITH care following AutoHSCT we undertook an
audit of our clinical outcomes.
Patient eligibility for Hospital-in-the-home (HITH) care
Patients undergoing autologous HSCT are referred to
the HITH service by the haematology team.
To be eligible for consideration for HITH care patients
must be undergoing autologous HSCT following either
LACE (Lomustine, Cytosine Arabinoside, Cyclophosph-
amide and Etoposide) or melphalan conditioning, give
informed consent, be over 18 years of age, medically
stable, have available appropriate carer supervision, have
a suitable home environment; be able to use their own
toilet and administer their own oral medication, have
access to a home telephone and available transport and be
compliant with therapy. Patients would not be considered
suitable for HITH care if they are: unable to comply with
these conditions, are geographically isolated (live more
than 45 minutes by road from hospital), unable to
understand or comply with treatment or require therapy
more than once per day.
Transplant conditioning
Patients with Hodgkin’s Lymphoma and non-
Hodgkin’s Lymphoma received transplant conditioning
with the LACE regimen. LACE consists of Lomustine
200mg/m2 orally on day 7, Etoposide 1000mg/m2 on day 7,
cytosine arabinoside 2g/m2 on days 6 and 5 and Cycloph-
osphamide 1.8g/m2 on days 4 to 2 inclusive.
Patients with multiple myeloma (MM) were conditioned
with melphalan 200mg/m2 given intravenously over 1 hour
on day 2.
Supportive care
Blood samples were collected daily for full blood count
(FBC) and biochemistry.
Red cell transfusions were given if the patient had a
haemoglobin (Hb) level less than 80g/L and platelet
transfusions when the platelet count fell below 10 x 109/L
or if there were signs of haemorrhage. All blood products
were irradiated.
All patients received mouth care and infective
prophylaxis with norfloxacin 400mg orally bd, aciclovir
400mg orally tds, fluconazole 200mg orally bd,
chlorhexidine mouthwash 10mls qid and nystatin oral
solution 1ml qid.
Granulocyte colony-stimulating factor (G-CSF) at
5mcg/kg per day was administered from day one after
stem cell transplantation until the Absolute Neutrophil
RESEARCH PAPER
35
Australian Journal of Advanced Nursing 2006 Volume 23 Number 4
Count (ANC) was greater than 0.5 x 109/L for two
consecutive days.
Veno-occlusive disease prophylaxis was with
enoxaparin 40mg SC daily.
Mucosal pain was initially treated with oral paracetamol
and oral morphine. If this was insufficient continuous
intravenous morphine was administered using a pump.
Post-transplant HITH care
All patients suitable for HITH care were provided with
an outpatient management plan prior to discharge with
details of the care to be provided by the HITH team and
indications for contacting the HITH nurse or attending the
haematology day ward or the emergency department.
HITH nurses attend patients daily to assess their
progress and administer therapy. Therapies commonly
administered by HITH staff include intravenous
antibiotics and subcutaneous injections such as G-CSF
and/or enoxaparin. At each daily visit the HITH nurse
performs a structured clinical assessment which records
details of a relevant history and examination including:
assessment of symptoms, temperature, pulse, blood
pressure, central venous access, oral mucosa, skin integrity,
oral intake, fluid balance, urine output and weight. All
toxicity grading is performed according to World Health
Organisation (WHO) guidelines with the results recorded
on a post-transplant flow sheet.
Post-transplant investigations (daily FBC, biochemistry
and urinalysis) are also attended by the HITH nursing staff.
The results of these routine investigations are then reviewed
by HITH nurses, who may then arrange outpatient
transfusion of red cells or platelets as necessary. Any
clinical concerns that the HITH care nurse has are
discussed with the attending haematologist, who may
choose to review the patient as an outpatient as necessary.
Clinical problems arising after working hours are addressed
by the medical registrar on-call and by the attending
haematologist. HITH patients requiring admission for
inpatient care are admitted to the haematology ward under
the care of the attending haematologist.
OUTCOME MEASURES
For the purpose of this audit descriptive data were
collected on age and gender, diagnosis, transplant
conditioning, inpatient length of stay (pre-discharge and
post-readmission), and duration of HITH care. Details of
a series of outcome measures that may be used as de-facto
indicators of the safety and feasibility of HITH care were
collected. These included patient-initiated telephone calls,
unscheduled staff call-outs, incidence of unplanned
readmission to hospital, reasons for readmission,
morbidity and toxicity (according to WHO criteria),
mortality (during admission and transplant-related
mortality at day 100), incidence of infection, antibiotic
use, incidence and severity of mucositis, incidence of
renal failure, bleeding incidence and severity (according
to WHO criteria) and transfusion requirements.
RESULTS
Patient characteristics
Between March 2001 and June 2003, 33 patients
underwent autologous HSCT for lymphoma or multiple
myeloma at the Hunter Haematology Unit. Of these, 16
were judged to be suitable candidates for HITH care post-
transplant and were offered the option. Unfortunately,
after consenting to HITH care three patients subsequently
developed medical complications necessitating inpatient
care for the duration of the treatment episode. The data
presented is on the 13 transplant recipients who received
HITH care following autologous HSCT. Of these
candidates 10 were males and three were females, giving
a 10:3 ratio of males to females. The average age was 48
years (sd14.83). For the transplant recipients not offered
HITH care, this decision was made on the following
grounds, six patients lived outside the agreed geographical
area, six were medically unstable, three lived alone, one
patient was assessed to be non-compliant with therapy
and one patient was excluded due to an unsuitable home
environment.
From the 13 patients treated under the HITH program,
nine received a LACE-conditioned transplant for lymphoma
and four received a melphalan-only conditioned transplant
for myeloma. Patients with lymphoma can be further
classified as two with diffuse large cell non-Hodgkins
lymphoma (NHL), two with follicular NHL, three with
Hodgkins lymphoma; and two with a diagnosis of other
forms of NHL (unclassified and small cell).
Table 1: Patient demographics
Age M/F Diagnosis Chemotherapy Readmission 
regime required Y/N
52 M HD LACE N
59 M NHL LACE N
50 M NHL LACE Y
32 M Lymphoma LACE Y
55 M NHL LACE Y
20 M HD LACE Y
59 M NHL LACE Y
22 F HD LACE Y
62 M NHL LACE Y
66 M Myeloma Melphalan Y
51 M Myeloma Melphalan Y
54 F Myeloma Melphalan Y
41 F Myeloma Melphalan Y
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Stem cell inoculum
Of the 13 patients who underwent autologous HSCT
for multiple myeloma or lymphoma, the mean stem cell
inoculum was 8.3 x 106/kg (range 1.8-20.2 x 106/kg).
Engraftment
Patients that underwent LACE conditioning achieved
neutrophil engraftment (0.5x109/L) by day +10 (range
day 9-12) and platelet engraftment (unsupported platelet
count > 50 x 109/L) by day +24 (range 13-35). Patients
conditioned with melphalan generally achieved neutrophil
engraftment by day +11 (range day +10-13) and platelet
engraftment by day +20 (range 15-25).
G-CSF use and transfusion support
Patients undergoing LACE conditioning received an
average of 11 daily doses of G-CSF (range 9-14 doses),
whereas patients receiving melphalan conditioning received
an average of 12 doses of G-CSF (range 10-13 doses).
The majority of transplant recipients did not require
significant blood product support. LACE-conditioned
transplant recipients required an average of 3 units of
packed cells (range 1-9) and 18 units of platelets (range 8-
32) while melphalan conditioned transplant recipients
required 3 units of packed cells (range 2-4) and 9 units of
platelets (range 4-12).
Transplant-related Toxicity 
Autologous HSCT with either LACE or melphalan
conditioning was generally well tolerated. The major
toxicity of transplantation was febrile neutropenia, which
accounted for the majority of readmissions but did not
result in the death of any transplant recipients. No patients
required intensive care admission. Of those patients who
underwent a LACE autograft, six patients experienced
grade 1 to grade 3 mucositis (mean grade 1), while all four
patients who underwent a melphalan autograft experienced
greater than grade 2 mucositis (mean grade 3). Of all the
patients who underwent HITH care, only five experienced
any bleeding complications, and in all cases this was mild
(grade 1). Only one patient developed renal dysfunction
with a transitory rise in the serum creatinine greater than
120ummol/L.
There were no deaths in the HITH cohort. All 13
patients managed at home on the HITH program were
alive on day +100 post-transplant with none demonstrating
evidence of disease progression.
Discharges from hospital
Two patients (15%) were discharged from hospital for
HITH care on the day of transplant; seven (53%) were
discharged on day +1 post-transplant; one (7.6%) on day
+2 and three (23%) left hospital on or after day +3.
Readmissions following HITH care
Eleven of the patients (84.6%) managed on the HITH
program required readmission to the haematology 
unit within 7 days of discharge from hospital. Febrile
neutropenia / sepsis accounted for 81.8% (n=9) of these
readmissions. Four of these patients did not have a
pathogen identified though two presented with symptoms
of severe mucositis. No evidence of line infections or
other specified sources were confirmed though blood
cultures were positive in five cases. Two patients had
blood cultures positive for strep viridens, one for E coli,
one for staph aureas, and one for a coagulase negative
staphylococcus. The readmission length of stay ranged
from 5 to 12 days (mean 8.5) and all patients were
discharged to their own homes at that time.
Of the remaining two patients requiring readmission to
hospital: one patient was admitted for treatment of a
venous thrombosis and one for management of severe
(grade 4) mucositis. All patients discharged for HITH
care on or after day +3 post-transplant required
readmission, suggesting that this group of patients may
not have been appropriate candidates for HITH care.
DISCUSSION
HSCT is an intensive treatment modality with a 100
day treatment related mortality (TRM) of 1-50%
depending on the type of transplant. In the past, the
toxicity associated with HSCT has mandated inpatient
care, with lengthy inpatient admissions. Developments in
transplantation and supportive care have made outpatient
care a possibility. The combination of antimicrobial
prophylaxis, simplified pre-transplant conditioning and
non-myeloablative regimens has made possible the
performance of HSCT entirely on an outpatient basis.
While only a small number of studies of outpatient HSCT
have been done, the results of published studies suggest
that outpatient HSCT can be achieved with equivalent
efficacy as inpatient transplantation and without an
increase in morbidity or mortality.
This report suggests that autologous transplantation
using a HITH care delivery model is feasible and is safe
for appropriately selected patients (40% of our patients)
with lymphoma and multiple myeloma. Our results also
suggest that there may be merit in exploring HITH
models of post-transplant care as a means for increasing
patient satisfaction with care and reducing the costs of care.
LIMITATIONS
There are a number of limitations to this report. We
report only a small cohort of HITH care patients
unmatched to IHC episodes and as such can make only
limited conclusions regarding adverse events and mortality
associated with HITH transplantation care. Patients were
also not randomised between inpatient care and HITH
care and indeed the rigorous selection criteria for HITH
care mean that a selection bias is inevitable with younger,
healthier, more compliant patients with less co-morbidity
more likely to be offered outpatient care post-transplant.
Finally, we also did not measure costs to families, carers
or the community and as such are unable to explore the
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degree of cost shifting that occurs with HITH
transplantation.
Whether our (ongoing) experience has any relevance to
other Australian transplant centres remains to be shown.
Newcastle is a small city (population 470,610) and traffic
congestion is mild compared with major metropolitan
centres. Whether HITH transplantation care can be
delivered successfully in other centres would require
consideration of local factors, including transport
infrastructure, hospital and transplant unit design and
organisational structure of outpatient and home care
services. Indeed, great care must be taken in extrapolating
from studies of HITH care, such as ours, as there may be
significant differences in conditions, in the model of
HITH care, in the financial and structural organisation of
health services and in the data gathered and reported by
the researchers (Ioannides-Demos et al 2001, KPMG
Consulting 1999).
The majority of participants in our HITH post-
transplant program required readmission to hospital
(n=11, 84.6%). In most instances this was because of the
development of febrile neutropenia. Importantly, none of
the patients experienced any clinical consequence as a
result of this infection and all were subsequently
discharged from hospital following engraftment. This is
an important finding as unexpected return to hospital
during HITH care can highlight difficulties with
eligibility criteria, care choice, skill of assessor, and poor
initial choice of therapy or misdiagnosis or can be an
indicator of an effective monitoring system, whereby
vigilant clinical supervision prevents an adverse negative
outcome (Montalto et al 1999).
While our readmission rate is substantially higher than
that reported in other studies, the absence of any major
toxicity would suggest that our results may be explained
by the absence of an outpatient care protocol for the
management of febrile neutropenia and by a liberal
readmission policy (Ruiz-Arguelles et al 1998; Jagannath
et al 1997).
While HITH care following HSCT appears to be an
attractive option, transfer of care to the outpatient setting
is not without its problems.
Compliance of patients with medical treatment cannot
be assured in the home with the same degree of certainty
that it can in hospital and earlier hospital discharge
following HSCT may be associated with a delay in
resumption of oral energy intake and discontinuation of
intravenous (IV) fluids (Stern et al 2000; Kane 1995).
Research from outpatient HSCT programs in the United
States of America has also found that loss of appetite,
fatigue, continuous low-grade nausea and insomnia may
frequently complicate outpatient care following transplan-
tation, despite increased patient and caregiver satisfaction
with outpatient care (Lawrence et al 1996). Indeed,
evidence that outcomes may be no better, or even worse,
than inpatient care has led some to express concern that
the impetus for change to outpatient models of care has
more to do with cost shifting than real concern for patient
welfare.
Given the intensity of treatment, the presence of
predictable neutropenia, the likelihood of adverse effects
related to transplant conditioning and the site of care
delivery, there will always be a predictable level of
expected and unexpected intervention associated with
HITH care for autologous HSCT. Enthusiasm for HITH
care must therefore be tempered by recognition that HITH
programs require a minimum level of infrastructure
support including, effective incorporation of pathology
services, 24-hour emergency care and telephone support,
a rigorous system of monitoring and evaluation and a
structured process for the return of HITH patients to
hospital. Such programs also require the availability of
nursing expertise for outpatient care, adequate
communication between medical and nursing staff and
between inpatient and outpatient services and the
availability of an outpatient clinic able to provide medical
assessment, transfusion services, intravenous infusions
and facilitated admission where appropriate. It must also
be stressed that outpatient care cannot be offered to all
patients and that a careful selection process is critical.
Only those who are compliant with therapy, able to attend
outpatient follow-up, have a suitable home environment,
have adequate support available 24 hours per day at home
and have a reasonable educational level, are candidates
for home care following transplantation.
Finally, as ambulatory / HITH care is a relatively new
development in medical service delivery, it is vital that
such programs be rigorously established and carefully
monitored in order to maximise their benefits for patients
and for government.
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